<DOC>
	<DOCNO>NCT00003312</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Giving radiation therapy seed implant prostate may kill tumor cell . PURPOSE : Phase II trial study effectiveness brachytherapy treat patient stage I stage II prostate cancer .</brief_summary>
	<brief_title>Brachytherapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate effectiveness transrectal ultrasound guide permanent radioactive implantation prostate patient confine adenocarcinoma prostate . II . Assess overall survival , disease specific survival , clinical relapse ( local distant ) , PSA level , genitourinary gastrointestinal morbidity implant patient . III . Assess quality life patient . OUTLINE : This multicenter study . Patients receive transrectal ultrasound guide radioactive I-125 seed implanted prostate . At least one week prior implant , patient undergo transurethral ultrasound study determine volume prostate . Following implantation , seed extrude bladder lodge urethral wall retrieve , extra seed may implant identify `` cold spot '' uniform seed distribution . Prostate rebiopsy require start hormonal therapy local progression biochemical failure without clear focus progression . Quality life assess every 3 month 1 year , every 6 month 1 year , annually 3 year . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 95 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally confine adenocarcinoma prostate Stage I II ( T1bc T2ab , NX , M0 ) PSA great 10 ng/mL Prostate volume transurethral ultrasound great 45/mm3 least 1 week , 4 week , prior implant Gleason score great 6 American Urological Association void symptom score great 12 No evidence distant metastases No lymph node involvement PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior concurrent malignancy within 5 year except basal squamous cell skin cancer No major medical psychiatric illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No prior hormonal therapy , include finasteride Radiotherapy : No prior pelvic radiotherapy Surgery : No prior radical surgery prostate cancer ( e.g. , transurethral prostatectomy ) No hip prosthesis</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>